Study Met Primary Endpoint; AIMS Response Rate Reached 76.5% in the 20mg Dose GroupShanghai, June 16, 2026 --Luye Pharma Group today announced that a Phase 2 clinical trial in China evaluating its LY0...
Recently, Australian Aurora Healthcare, asubsidiaryof Luye Medical Group, officially signed a strategic cooperation agreement with Tencent Health, aiming to deploy Tencent Health’s AI‑centric s...
Boan Biotech announced today that China’s National Medical Products Administration (NMPA) has approved the supplemental application for Boluojia® (denosumab injection 120 mg) for the treatment o...
Shanghai, April 20th, 2026 —Luye Pharma Group today announced that the first subject has been enrolled in a U.S. pharmacokinetic (PK) bridging clinical trial of its new molecular entity LY03015. This...
●Accelerated and upgraded innovation●Empowerment through partnerships●Two consecutive years of profitabilityYantai, China, March 30, 2026 — Boan Biotech (6955.HK) today announced its annual result...
Shanghai, March 13, 2026 — Luye Pharma Group today announced a strategic partnership with Sinopharm Group Co. Ltd. (Sinopharm Group) and its subsidiary China National Medicines Corporation Ltd. (Sino...
Shanghai, January 8, 2026 —Luye Pharma Group today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the New Drug Appli...
Recently, as a partner of the "Peking University Luye Biomedical Innovation Fund," Luye Life Sciences Group was invited to visit Peking University. The delegation, including Mr. Yang Liang, ...
Shanghai, December 7, 2025 – Luye Pharma Group today announced that five new products have been included in the 2025 edition of the National Reimbursement Drug List for Basic Medical Insurance, ...
Boan Biotech today announced that its aflibercept intravitreous injection Boyoujing® has been approved by China’s National Medical Products Administration (NMPA) for the treatment of neovascular...
TOP